Skip to content

Early Detection of Vaping-related Vascular Diseases

Early Detection of Vaping-related Vascular Diseases

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05454267
Acronym
ENDS
Enrollment
90
Registered
2022-07-12
Start date
2022-09-12
Completion date
2027-12-31
Last updated
2026-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Blood Vessel Injury, Vaping

Brief summary

The purpose of this study is to determine how vaping affects blood vessels, in particular if early damage occurs in the lung vessels.

Interventions

None listed

Sponsors

University of Miami
Lead SponsorOTHER
Florida Department of Health
CollaboratorOTHER_GOV

Study design

Observational model
OTHER
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
18 Years to 40 Years
Healthy volunteers
Yes

Inclusion criteria

Vapers Group: 1. Current electronic cigarette (EC) Puff Bar users defined as using EC either daily or occasionally in the past 30 days for at least 6 months, and with 5% nicotine concentration pods. 2. Adults aged 18-40 years Healthy Group: 1. Healthy never smokers, never vapers 2. Adults aged 18-40 years

Exclusion criteria

1. Current or past smoking of tobacco cigarette (TC) or other tobacco/nicotine products (e.g., smokeless tobacco, Hookah) or marijuana will be excluded from the study. 2. Subjects with self-reported history of chronic health problems including asthma, chronic obstructive pulmonary disease (COPD), morbid obesity (BMI\>40 kg/m2), hypertension or diabetes 3. Pregnant or breastfeeding women

Design outcomes

Primary

MeasureTime frameDescription
Airway blood flow reactivity (QAW)Up to 1 weekQAW will be measured via soluble gas uptake method
Pulmonary vascular resistance (PVR)Up to 4 weeksPVR will be measured via echocardiography
Flow-mediated vasodilation (FMD)Up to 4 weeksFMD will be measured by blood pressure cuff deflation using ultrasound

Countries

United States

Contacts

CONTACTAdam Wanner, MD
awanner@med.miami.edu(305)243-2568
CONTACTMichael Campos, MD
mcampos1@med.miami.edu3052436388
PRINCIPAL_INVESTIGATORAdam Wanner, MD

University of Miami

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 16, 2026